Skip to main content
Yuyu Pharma, Inc. logo

Yuyu Pharma, Inc. — Investor Relations & Filings

Ticker · 000220 ISIN · KR7000220004 KO Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2020-12-01 Director's Dealing
Country KR South Korea
Listing KO 000220

About Yuyu Pharma, Inc.

https://www.yuyu.co.kr/

Yuyu Pharma, Inc., established in 1941, is a healthcare company focused on the development, manufacturing, and marketing of pharmaceutical products. The company is committed to creating innovative therapeutics to address healthcare challenges and improve quality of life. Its research and development efforts are concentrated on key therapeutic areas, with a notable emphasis on treatments for central nervous system disorders, including Alzheimer's disease. The company operates through several divisions, including Yuyu Healthcare, which provides pharmaceutical-standard Original Design Manufacturer (ODM) and Original Equipment Manufacturer (OEM) services.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This document details the share ownership and changes in holdings by a company executive (Yoo Kyung-soo of Yuyu Pharma). In the context of financial filings, reports detailing personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2020-12-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when a person or entity acquires a significant stake (typically 5% or more) in a listed company. It details the reporter, special related parties, the number of shares held, the purpose of holding, and changes in shareholdings (in this case, acquisition of convertible bonds and additional stock collateral). This fits the definition of a 'Major Shareholding Notification' (MRQ).
2020-11-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by Yuyu Pharma. This is a standard regulatory filing in South Korea (DART system) where directors or major shareholders report changes in their personal holdings of company securities. This falls under the category of 'Director's Dealing' (DIRS) as it details personal share/convertible bond transactions by an executive (CEO).
2020-11-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders (directors, officers, and major shareholders) to disclose changes in their shareholdings or equity-linked securities. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions and ownership changes by company executives.
2020-11-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors and executives. In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS), which covers personal share transactions and ownership changes by company insiders.
2020-11-24 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Yuyu Pharma, covering the period from January 1, 2020, to September 30, 2020. It contains detailed financial information, business descriptions, capital structure, and management discussions, which are characteristic of an interim financial report. It is not an announcement of a report (RPA) or a simple certification, as it contains substantive financial data and operational details. 9M 2020
2020-11-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.